The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-0604
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Barantsevich E.R.

Pavlov First Saint Petersburg State Medical University

Kurushina O.V.

Volgograd State Medical University

Akhmadeeva L.R.

Bashkir State Medical University

Skoromets A.P.

Pavlov First Saint Petersburg State Medical University

Belova A.N.

Privolzhsky Research Medical University

Mendelevich E.G.

Kazan State Medical University

Kovalchuk V.V.

Semashko City Hospital No. 38

Doronina O.B.

Sibneiromed

Barkhatov M.V.

Federal Siberian Scientific and Clinical Center

Kamchatnov P.R.

Pirogov Russian National Research Medical University

Bioregulatory drug Newrexan in the treatment of anxiety and dissomnia. Resolution of the Council of Experts (June 8, 2023)

Authors:

Barantsevich E.R., Kurushina O.V., Akhmadeeva L.R., Skoromets A.P., Belova A.N., Mendelevich E.G., Kovalchuk V.V., Doronina O.B., Barkhatov M.V., Kamchatnov P.R.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2023;123(7): 143‑146

DOI: 10.17116/jnevro2023123071143

Views: 5984

Downloaded: 68

Download PDF (RU)
Contact the author
Table of contents

BIOREGULATORY DRUG NEWREXAN IN THE TREATMENT OF ANXIETY AND DISSOMNIA. RESOLUTION OF THE COUNCIL OF EXPERTS (JUNE 8, 2023)
BIOREGULATORY DRUG NEWREXAN IN THE TREATMENT OF ANXIETY AND DISSOMNIA. RESOLUTION OF THE COUNCIL OF EXPERTS (JUNE 8, 2023)

To cite this article:

Barantsevich ER, Kurushina OV, Akhmadeeva LR, et al. . Bioregulatory drug Newrexan in the treatment of anxiety and dissomnia. Resolution of the Council of Experts (June 8, 2023). S.S. Korsakov Journal of Neurology and Psychiatry. 2023;123(7):143‑146. (In Russ.)
https://doi.org/10.17116/jnevro2023123071143

Подписка 2025-2 (S.S. Korsakov Journal of Neurology and Psychiatry)
 
МСФ на ЯМ
Close metadata

Bioregulatory drug Newrexan in the treatment of anxiety and dissomnia. Resolution of the Council of Experts.

Authors:

Barantsevich E.R.

Pavlov First Saint Petersburg State Medical University

Kurushina O.V.

Volgograd State Medical University

Akhmadeeva L.R.

Bashkir State Medical University

Skoromets A.P.

Pavlov First Saint Petersburg State Medical University

Belova A.N.

Privolzhsky Research Medical University

Mendelevich E.G.

Kazan State Medical University

Kovalchuk V.V.

Semashko City Hospital No. 38

Doronina O.B.

Sibneiromed

Barkhatov M.V.

Federal Siberian Scientific and Clinical Center

Kamchatnov P.R.

Pirogov Russian National Research Medical University

Received:

19.06.2023

Accepted:

26.06.2023

List of references:

  1. Gradus JL. Prevalence and prognosis of stress disorders: A review of the epidemiologic literature. Clin Epidemiol. 2017;9:251-260.  https://doi.org/10.2147/CLEP.S106250
  2. Bildanova VR, Biserova GK, Shagivaleeva GR. Psychology of stress and methods of its prevention: Training manual. Elabuga: Publishing house of EI KFU; 2015. (In Russ.).
  3. Slavich GM. Life Stress and Health: A Review of Conceptual Issues and Recent Findings. Teaching Psychol. 2016;43(4):346-355.  https://doi.org/10.1177/0098628316662768
  4. Akarachkova ES, Kotova OV, Vershinina SV. Algorithm for the diagnosis, treatment, and prevention of stress (for general practitioners). Therapeutic Archives. 2015;6:102-107. (In Russ.). https://doi.org/10.17116/terarkh2015876102-107
  5. Han KS, Kim L, Shim I. Stress and sleep disorder. Experimental Neurobiol. 2012;21(4):141-150.  https://doi.org/10.5607/en.2012.21.4.141
  6. Fernandez-Mendoza J, Vgontzas AN. Insomnia and its impact on physical and mental health. Curr Psychiatry Rep. 2013;15(12):418.  https://doi.org/10.1007/s11920-013-0418-8
  7. Riemann D, Baglioni C, Bassetti C, et al. European guideline for the diagnosis and treatment of insomnia. J Sleep Res. 2017;26(6):675-700.  https://doi.org/10.1111/jsr.12594
  8. Roy L, Birrell J, Wells J, Abba N. SH CP 136 Guidelines for Treatment of Primary Insomnia. South Heal NHS Found Trust. 2019;Version 3:1-4. 
  9. Kripke DF. Hypnotic drug risks of mortality, infection, depression, and cancer: but lack of benefit. F1000Research. 2016;5:918.  https://doi.org/10.12688/f1000research.8729.3
  10. Doering BK, Wegner A, Hadamitzky M, et al. Effects of Neurexan® in an experimental acute stress setting — An explorative double-blind study in healthy volunteers. Life Sci. 2016;146:139-147.  https://doi.org/10.1016/j.lfs.2015.12.058
  11. Dimpfel W. Effects of Neurexan® on Stress-Induced Changes of Spectral EEG Power: A Double-Blind, Randomized, Placebo-Controlled, Crossover Exploratory Trial in Human Volunteers. World J Neurosci. 2019;9:100-112.  https://doi.org/10.4236/wjns.2019.93007
  12. Mayer K, Krylova M, Alizadeh S. Nx4 Reduced Susceptibility to Distraction in an Attention Modulation Task. Front Psychiatry. 2021;12:746215. https://doi.org/10.3389/fpsyt.2021.746215
  13. Herrmann L, Vicheva P, Kasties V et al. fMRI revealed reduced amygdala activation after Nx4 in mildly to moderately stressed healthy volunteers in a randomized, placebo-controlled, cross-over trial. Sci Rep. 2020;10(1):3802.24  https://doi.org/10.1038/s41598-020-60392-w
  14. Chand T, Alizadeh S, Jamalabadi H. et al. EEG revealed improved vigilance regulation after stress exposure under Nx4 — A randomized, placebo-controlled, double-blind, cross-over trial. IBRO Neurosci Rep. 2021;11:175-182.  https://doi.org/10.1016/j.ibneur.2021.09.002
  15. Herrmann L, Kasties V, Boden C, et al. Nx4 attenuated stress-induced activity of the anterior cingulate cortex. A post hoc analysis of a randomized placebo-controlled crossover trial. Human Psychopharmacol Clin Experiment. 2022;37(5):e2837. https://doi.org/10.1002/hup.2837
  16. Chand T, Alizadeh S, Li M, et al. Nx4 Modulated Resting State Functional Connectivity between Amygdala and Prefrontal Cortex in a Placebo-Controlled, Crossover Trial. Brain Connectivity. 2022;12(9):812-822.  https://doi.org/10.1089/brain.2021.0189

Close metadata

Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.